PET scan to predict immunotherapy success in DLBCL
Part of Blood & lymphatic, Cancer, Genetic & congenital, Hormones & metabolism, Immune system & allergy, Skin clinical trials.
This trial uses a special PET scan to see if a protein called Granzyme B can predict how well immunotherapy will work for people with DLBCL. It aims to help doctors know earlier if treatment is effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL).
- Your overall health should be good enough that you are expected to live more than 6 months.
- You must sign a consent form agreeing to take part in the study.
- You cannot have other active cancers.
- You cannot be pregnant, breastfeeding, or at risk of pregnancy.
- You must be able to follow the study instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
This study looks for biomarkers (biological signs) in blood or tissue samples from people with diffuse large B-cell lymphoma (DLBCL) to help predict how the disease behaves and how well treatment might work. Participation involves giving extra biopsy or blood samples during routine care.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This trial tests a new type of PET scan (Granzyme B-PET) to see if it can predict how well immunotherapy will work for people with triple-negative breast cancer that has spread. If it works, doctors might be able to tell sooner whether treatment is helping.
This study uses a special PET scan to look for a protein called Granzyme B in your body, which may help predict how well treatment will work in T-NK cell lymphoma. It aims to see if this imaging can guide treatment decisions.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working in people with advanced liver or bile duct cancer. The goal is to find a better way to monitor treatment response.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.